Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Motion Sifnos: A randomized, double-blind, placebo-controlled study demonstrating the effectiveness of tradipitant in the treatment of motion sickness

View ORCID ProfileVasilios M. Polymeropoulos, View ORCID ProfileMark É. Czeisler, Mary M. Gibson, Austin A. Anderson, Jane Miglo, Jingyuan Wang, Changfu Xiao, View ORCID ProfileChristos M. Polymeropoulos, Gunther Birznieks, View ORCID ProfileMihael H. Polymeropoulos
doi: https://doi.org/10.1101/2020.04.06.20055715
Vasilios M. Polymeropoulos
1Vanda Pharmaceuticals, Washington, District of Columbia, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Vasilios M. Polymeropoulos
  • For correspondence: Vasilios.Polymeropoulos{at}vandapharma.com
Mark É. Czeisler
1Vanda Pharmaceuticals, Washington, District of Columbia, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mark É. Czeisler
Mary M. Gibson
1Vanda Pharmaceuticals, Washington, District of Columbia, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Austin A. Anderson
1Vanda Pharmaceuticals, Washington, District of Columbia, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jane Miglo
1Vanda Pharmaceuticals, Washington, District of Columbia, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jingyuan Wang
1Vanda Pharmaceuticals, Washington, District of Columbia, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Changfu Xiao
1Vanda Pharmaceuticals, Washington, District of Columbia, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christos M. Polymeropoulos
1Vanda Pharmaceuticals, Washington, District of Columbia, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Christos M. Polymeropoulos
Gunther Birznieks
1Vanda Pharmaceuticals, Washington, District of Columbia, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mihael H. Polymeropoulos
1Vanda Pharmaceuticals, Washington, District of Columbia, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mihael H. Polymeropoulos
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Novel therapies are needed for the treatment of motion sickness given the inadequate relief, and bothersome and dangerous adverse effects of currently approved therapies. Neurokinin-1 (NK1) receptor antagonists have the potential to be effective in improving the symptoms of motion sickness, given the involvement of Substance P in nauseogenic and emetic pathways and the expression of NK1 receptors in the gastrointestinal system. Here, we evaluated the efficacy of tradipitant, a novel NK1 receptor antagonist, in preventing motion sickness in variable sea conditions.

Methods A total of 126 adults participated in the Motion Sifnos Study. Groups of participants were assigned to one of seven boat trips lasting approximately four hours on the Pacific Ocean. Participants were randomized 1:1 to tradipitant 170 mg or placebo and completed the Motion Sickness Severity Scale (MSSS) every 30 minutes, in addition to other assessments. Severity of motion sickness was assessed with the incidence of vomiting and the MSSS.

Results Participants on tradipitant had a significantly lower incidence of vomiting as compared to those on placebo across all boat trips (tradipitant=17.5%, placebo=39.7%, p=0.0039). For trips exposed to rough sea conditions, the difference in the incidence of vomiting between the groups was more dramatic (tradipitant=15.79%, placebo=72.22%, p=0.0009). Across these trips, motion sickness symptoms were significantly lower in the tradipitant group compared to the placebo group (tradipitant=3.19, placebo=4.57, p=0.0235).

Discussion Tradipitant has the potential to be an effective therapy for the prevention of vomiting and treatment of nausea in people with motion sickness.

Competing Interest Statement

All authors are current or previous of employees of Vanda Pharmaceuticals. The clinical trial was sponsored by Vanda Pharmaceuticals.

Clinical Trial

NCT03772340

Funding Statement

The clinical trial was sponsored by Vanda Pharmaceuticals.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All datasets included in this study are in the article/supplemental files.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted April 11, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Motion Sifnos: A randomized, double-blind, placebo-controlled study demonstrating the effectiveness of tradipitant in the treatment of motion sickness
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Motion Sifnos: A randomized, double-blind, placebo-controlled study demonstrating the effectiveness of tradipitant in the treatment of motion sickness
Vasilios M. Polymeropoulos, Mark É. Czeisler, Mary M. Gibson, Austin A. Anderson, Jane Miglo, Jingyuan Wang, Changfu Xiao, Christos M. Polymeropoulos, Gunther Birznieks, Mihael H. Polymeropoulos
medRxiv 2020.04.06.20055715; doi: https://doi.org/10.1101/2020.04.06.20055715
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Motion Sifnos: A randomized, double-blind, placebo-controlled study demonstrating the effectiveness of tradipitant in the treatment of motion sickness
Vasilios M. Polymeropoulos, Mark É. Czeisler, Mary M. Gibson, Austin A. Anderson, Jane Miglo, Jingyuan Wang, Changfu Xiao, Christos M. Polymeropoulos, Gunther Birznieks, Mihael H. Polymeropoulos
medRxiv 2020.04.06.20055715; doi: https://doi.org/10.1101/2020.04.06.20055715

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Primary Care Research
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)